✦ LIBER ✦

Management of advanced stage intermediate grade non-Hodgkin's lymphomas

✍ Scribed by Dr. Raymond H. S. Liang; Edmond K. W. Chiu; T. K. Chan; David Todd; S. L. Loke

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 438 KB
Volume: 8
Category: Article
ISSN: 0278-0232
DOI: 10.1002/hon.2900080306

No coin nor oath required. For personal study only.

✦ Synopsis

The treatment result of271 cases ofadvanced stage intermediate grade lymphoma were reviewed. Ninety-four patients received CHOP chemotherapy, 45 BACOP and 17 m-BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease-free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m-BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.

📜 SIMILAR VOLUMES

Non-Hodgkin's Lymphomas.Advances in diag

Non-Hodgkin's Lymphomas.Advances in diagnosis, staging, and management

✍ Carol S. Portlock 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB

Value of radiation therapy in the manage

Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma

✍ Amr Aref; Samir Narayan; Samuel Tekyi-Mensah; Mary Varterasian; Maria Dan; David 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

The purpose of this study was to evaluate the probability and extent of response to radiation therapy in patients with chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma. Thirty-five patients with chemotherapy-resistant non-Hodgkin's lymphoma received local radiation therapy after init

The management of early-stage aggressive

The management of early-stage aggressive non-Hodgkin's lymphoma

✍ Professor A. Horwich; C. N. Catton; M. Quigley; D. Easton; M. Brada 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Sixty-one patients with stage I or I1 non-Hodgkin's lymphoma of aggressive histological subtype were treated at The Royal Marsden Hospital between 1972 and 1984. The overall 5-year survival probability was 69 per cent (60 per cent continuously relapse-free). The 5-year survival probability was 80 pe

Cladribine in the treatment of advanced

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

✍ Anil Tulpule; Gary Schiller; Laura A. Harvey-Buchanan; Myung Lee; Byron M. Espin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog with cytotoxic activity against both resting and proliferating cells. Clinical studies with cladribine have reported antitumor activity against various hematologic malignancies.

Non-Hodgkin's lymphoma of the larynx (St

Non-Hodgkin's lymphoma of the larynx (Stage IE)

✍ Kate Morgan; Kenneth A. Maclennan; Anthony Narula; Patrick J. Bradley; David A. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 612 KB

An alternating chemotherapy combination

An alternating chemotherapy combination (macoble) for intermediate and high-grade non-hodgkin's lymphoma

✍ M. Harding; L. McNulty; J. Paul; F. Lee; D. Dunlop; M. Soukop 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB 👁 1 views

48 patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL) received a CHOP based combination with the addition of etoposide on days 1 and 2, bleomycin days 1 and 10 and methotrexate 1.5 g/m2 on day 10 (MACOBLE). Their median age was 59 years, 20 (42 per cent) had an ECOG performance s